Text Size

Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation

This study has been completed.
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00170170
First received: September 13, 2005
Last updated: February 1, 2010
Last verified: February 2010
History of Changes
  Purpose

This study will investigate the clinical variables that may be used to predict who among the solid organ transplant recipients will develop cytomegalovirus (CMV) disease after completing antiviral prophylaxis.


Condition
Transplantation
Infection
Cytomegalovirus Infections

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Clinical Predictors of Late-onset CMV Disease in Solid Organ Transplant Recipients: A Strategy to Improve the Benefits and Reduce the Risks of Anti-CMV Prophylaxis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Enrollment: 500
Study Start Date: November 2004
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Detailed Description:

This study will investigate the clinical and laboratory variables that may be used to predict who among the solid organ transplant recipients will develop CMV disease after completing antiviral prophylaxis. This is a retrospective study of patients seen at the Mayo Clinic during the past five years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Recipients of liver, kidney, pancreas, heart or lung transplantation

Criteria

Inclusion Criteria:

  • Recipients of liver, kidney, pancreas, heart or lung transplantation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00170170

Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Roche Pharma AG
Investigators
Principal Investigator: Raymund R. Razonable, M.D. Mayo Clinic
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00170170     History of Changes
Other Study ID Numbers: 2275-04, VAL101
Study First Received: September 13, 2005
Last Updated: February 1, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
cytomegalovirus

Additional relevant MeSH terms:
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on May 16, 2013